 | • レポートコード：MRC2-11QY06365 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は巣状分節性糸球体硬化症薬のグローバル市場について調査・分析したレポートです。種類別（ロスマピモド、SHP-627、スパルセンタン、TM-5484、その他）市場規模、用途別（クリニック、研究センター、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別巣状分節性糸球体硬化症薬の競争状況、市場シェア ・世界の巣状分節性糸球体硬化症薬市場：種類別市場規模 2015年-2020年（ロスマピモド、SHP-627、スパルセンタン、TM-5484、その他） ・世界の巣状分節性糸球体硬化症薬市場：種類別市場規模予測 2021年-2026年（ロスマピモド、SHP-627、スパルセンタン、TM-5484、その他） ・世界の巣状分節性糸球体硬化症薬市場：用途別市場規模 2015年-2020年（クリニック、研究センター、病院、その他） ・世界の巣状分節性糸球体硬化症薬市場：用途別市場規模予測 2021年-2026年（クリニック、研究センター、病院、その他） ・北米の巣状分節性糸球体硬化症薬市場分析：米国、カナダ ・ヨーロッパの巣状分節性糸球体硬化症薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの巣状分節性糸球体硬化症薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の巣状分節性糸球体硬化症薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの巣状分節性糸球体硬化症薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Complexa Inc、Dimerix Bioscience Pty Ltd、GlaxoSmithKline Plc、Retrophin Inc、Takeda、Variant Pharmaceuticals Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis Drug Market
The global Focal Segmental Glomerulosclerosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Focal Segmental Glomerulosclerosis Drug Scope and Market Size
Focal Segmental Glomerulosclerosis Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Focal Segmental Glomerulosclerosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Focal Segmental Glomerulosclerosis Drug market is segmented into
Losmapimod
SHP-627
Sparsentan
TM-5484
Others
Segment by Application, the Focal Segmental Glomerulosclerosis Drug market is segmented into
Clinic
Research Center
Hospital
Others
Regional and Country-level Analysis
The Focal Segmental Glomerulosclerosis Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Focal Segmental Glomerulosclerosis Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Focal Segmental Glomerulosclerosis Drug Market Share Analysis
Focal Segmental Glomerulosclerosis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Focal Segmental Glomerulosclerosis Drug business, the date to enter into the Focal Segmental Glomerulosclerosis Drug market, Focal Segmental Glomerulosclerosis Drug product introduction, recent developments, etc.
The major vendors covered:
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Retrophin Inc
Takeda
Variant Pharmaceuticals Inc
…
1 Study Coverage
1.1 Focal Segmental Glomerulosclerosis Drug Product Introduction
1.2 Market Segments
1.3 Key Focal Segmental Glomerulosclerosis Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate by Type
1.4.2 Losmapimod
1.4.3 SHP-627
1.4.4 Sparsentan
1.4.5 TM-5484
1.4.6 Others
1.5 Market by Application
1.5.1 Global Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Research Center
1.5.4 Hospital
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Focal Segmental Glomerulosclerosis Drug Market Size, Estimates and Forecasts
2.1.1 Global Focal Segmental Glomerulosclerosis Drug Revenue 2015-2026
2.1.2 Global Focal Segmental Glomerulosclerosis Drug Sales 2015-2026
2.2 Global Focal Segmental Glomerulosclerosis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Focal Segmental Glomerulosclerosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Focal Segmental Glomerulosclerosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Focal Segmental Glomerulosclerosis Drug Competitor Landscape by Players
3.1 Focal Segmental Glomerulosclerosis Drug Sales by Manufacturers
3.1.1 Focal Segmental Glomerulosclerosis Drug Sales by Manufacturers (2015-2020)
3.1.2 Focal Segmental Glomerulosclerosis Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Focal Segmental Glomerulosclerosis Drug Revenue by Manufacturers
3.2.1 Focal Segmental Glomerulosclerosis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Focal Segmental Glomerulosclerosis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Focal Segmental Glomerulosclerosis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Focal Segmental Glomerulosclerosis Drug Revenue in 2019
3.2.5 Global Focal Segmental Glomerulosclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Focal Segmental Glomerulosclerosis Drug Price by Manufacturers
3.4 Focal Segmental Glomerulosclerosis Drug Manufacturing Base Distribution, Product Types
3.4.1 Focal Segmental Glomerulosclerosis Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Focal Segmental Glomerulosclerosis Drug Product Type
3.4.3 Date of International Manufacturers Enter into Focal Segmental Glomerulosclerosis Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Focal Segmental Glomerulosclerosis Drug Market Size by Type (2015-2020)
4.1.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2015-2020)
4.1.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2015-2020)
4.1.3 Focal Segmental Glomerulosclerosis Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Focal Segmental Glomerulosclerosis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Focal Segmental Glomerulosclerosis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Focal Segmental Glomerulosclerosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Focal Segmental Glomerulosclerosis Drug Market Size by Application (2015-2020)
5.1.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2015-2020)
5.1.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2015-2020)
5.1.3 Focal Segmental Glomerulosclerosis Drug Price by Application (2015-2020)
5.2 Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Focal Segmental Glomerulosclerosis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Focal Segmental Glomerulosclerosis Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Focal Segmental Glomerulosclerosis Drug by Country
6.1.1 North America Focal Segmental Glomerulosclerosis Drug Sales by Country
6.1.2 North America Focal Segmental Glomerulosclerosis Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Type
6.3 North America Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis Drug by Country
7.1.1 Europe Focal Segmental Glomerulosclerosis Drug Sales by Country
7.1.2 Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Type
7.3 Europe Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Focal Segmental Glomerulosclerosis Drug by Region
8.1.1 Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Region
8.1.2 Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Type
8.3 Asia Pacific Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Focal Segmental Glomerulosclerosis Drug by Country
9.1.1 Latin America Focal Segmental Glomerulosclerosis Drug Sales by Country
9.1.2 Latin America Focal Segmental Glomerulosclerosis Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Type
9.3 Central & South America Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Focal Segmental Glomerulosclerosis Drug by Country
10.1.1 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country
10.1.2 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Type
10.3 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Complexa Inc
11.1.1 Complexa Inc Corporation Information
11.1.2 Complexa Inc Description and Business Overview
11.1.3 Complexa Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Complexa Inc Focal Segmental Glomerulosclerosis Drug Products Offered
11.1.5 Complexa Inc Related Developments
11.2 Dimerix Bioscience Pty Ltd
11.2.1 Dimerix Bioscience Pty Ltd Corporation Information
11.2.2 Dimerix Bioscience Pty Ltd Description and Business Overview
11.2.3 Dimerix Bioscience Pty Ltd Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Products Offered
11.2.5 Dimerix Bioscience Pty Ltd Related Developments
11.3 GlaxoSmithKline Plc
11.3.1 GlaxoSmithKline Plc Corporation Information
11.3.2 GlaxoSmithKline Plc Description and Business Overview
11.3.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Products Offered
11.3.5 GlaxoSmithKline Plc Related Developments
11.4 Retrophin Inc
11.4.1 Retrophin Inc Corporation Information
11.4.2 Retrophin Inc Description and Business Overview
11.4.3 Retrophin Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Products Offered
11.4.5 Retrophin Inc Related Developments
11.5 Takeda
11.5.1 Takeda Corporation Information
11.5.2 Takeda Description and Business Overview
11.5.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Takeda Focal Segmental Glomerulosclerosis Drug Products Offered
11.5.5 Takeda Related Developments
11.6 Variant Pharmaceuticals Inc
11.6.1 Variant Pharmaceuticals Inc Corporation Information
11.6.2 Variant Pharmaceuticals Inc Description and Business Overview
11.6.3 Variant Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Products Offered
11.6.5 Variant Pharmaceuticals Inc Related Developments
11.1 Complexa Inc
11.1.1 Complexa Inc Corporation Information
11.1.2 Complexa Inc Description and Business Overview
11.1.3 Complexa Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Complexa Inc Focal Segmental Glomerulosclerosis Drug Products Offered
11.1.5 Complexa Inc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Focal Segmental Glomerulosclerosis Drug Market Estimates and Projections by Region
12.1.1 Global Focal Segmental Glomerulosclerosis Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Regions 2021-2026
12.2 North America Focal Segmental Glomerulosclerosis Drug Market Size Forecast (2021-2026)
12.2.1 North America: Focal Segmental Glomerulosclerosis Drug Sales Forecast (2021-2026)
12.2.2 North America: Focal Segmental Glomerulosclerosis Drug Revenue Forecast (2021-2026)
12.2.3 North America: Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Focal Segmental Glomerulosclerosis Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Focal Segmental Glomerulosclerosis Drug Sales Forecast (2021-2026)
12.3.2 Europe: Focal Segmental Glomerulosclerosis Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Focal Segmental Glomerulosclerosis Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Focal Segmental Glomerulosclerosis Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Focal Segmental Glomerulosclerosis Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Focal Segmental Glomerulosclerosis Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Focal Segmental Glomerulosclerosis Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Focal Segmental Glomerulosclerosis Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Focal Segmental Glomerulosclerosis Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Focal Segmental Glomerulosclerosis Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Focal Segmental Glomerulosclerosis Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Focal Segmental Glomerulosclerosis Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Focal Segmental Glomerulosclerosis Drug Market Segments
Table 2. Ranking of Global Top Focal Segmental Glomerulosclerosis Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Losmapimod
Table 5. Major Manufacturers of SHP-627
Table 6. Major Manufacturers of Sparsentan
Table 7. Major Manufacturers of TM-5484
Table 8. Major Manufacturers of Others
Table 9. Global Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Focal Segmental Glomerulosclerosis Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Focal Segmental Glomerulosclerosis Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Focal Segmental Glomerulosclerosis Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Focal Segmental Glomerulosclerosis Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Focal Segmental Glomerulosclerosis Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Focal Segmental Glomerulosclerosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Focal Segmental Glomerulosclerosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Focal Segmental Glomerulosclerosis Drug as of 2019)
Table 18. Focal Segmental Glomerulosclerosis Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Focal Segmental Glomerulosclerosis Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Focal Segmental Glomerulosclerosis Drug Price (2015-2020) (USD/Pcs)
Table 21. Focal Segmental Glomerulosclerosis Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Focal Segmental Glomerulosclerosis Drug Product Type
Table 23. Date of International Manufacturers Enter into Focal Segmental Glomerulosclerosis Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Focal Segmental Glomerulosclerosis Drug Sales Share by Type (2015-2020)
Table 27. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Focal Segmental Glomerulosclerosis Drug Revenue Share by Type (2015-2020)
Table 29. Focal Segmental Glomerulosclerosis Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Focal Segmental Glomerulosclerosis Drug Sales Share by Application (2015-2020)
Table 32. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2015-2020)
Table 34. North America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Focal Segmental Glomerulosclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2015-2020)
Table 38. North America Focal Segmental Glomerulosclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Focal Segmental Glomerulosclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Focal Segmental Glomerulosclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2015-2020)
Table 72. Complexa Inc Corporation Information
Table 73. Complexa Inc Description and Major Businesses
Table 74. Complexa Inc Focal Segmental Glomerulosclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Complexa Inc Product
Table 76. Complexa Inc Recent Development
Table 77. Dimerix Bioscience Pty Ltd Corporation Information
Table 78. Dimerix Bioscience Pty Ltd Description and Major Businesses
Table 79. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Dimerix Bioscience Pty Ltd Product
Table 81. Dimerix Bioscience Pty Ltd Recent Development
Table 82. GlaxoSmithKline Plc Corporation Information
Table 83. GlaxoSmithKline Plc Description and Major Businesses
Table 84. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. GlaxoSmithKline Plc Product
Table 86. GlaxoSmithKline Plc Recent Development
Table 87. Retrophin Inc Corporation Information
Table 88. Retrophin Inc Description and Major Businesses
Table 89. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Retrophin Inc Product
Table 91. Retrophin Inc Recent Development
Table 92. Takeda Corporation Information
Table 93. Takeda Description and Major Businesses
Table 94. Takeda Focal Segmental Glomerulosclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Takeda Product
Table 96. Takeda Recent Development
Table 97. Variant Pharmaceuticals Inc Corporation Information
Table 98. Variant Pharmaceuticals Inc Description and Major Businesses
Table 99. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Variant Pharmaceuticals Inc Product
Table 101. Variant Pharmaceuticals Inc Recent Development
Table 102. Global Focal Segmental Glomerulosclerosis Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 103. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share Forecast by Regions (2021-2026)
Table 104. Global Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 105. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 106. North America: Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 107. North America: Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 108. Europe: Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 109. Europe: Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Asia Pacific: Focal Segmental Glomerulosclerosis Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 111. Asia Pacific: Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 112. Latin America: Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 113. Latin America: Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 114. Middle East and Africa: Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 115. Middle East and Africa: Focal Segmental Glomerulosclerosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 116. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 117. Key Challenges
Table 118. Market Risks
Table 119. Main Points Interviewed from Key Focal Segmental Glomerulosclerosis Drug Players
Table 120. Focal Segmental Glomerulosclerosis Drug Customers List
Table 121. Focal Segmental Glomerulosclerosis Drug Distributors List
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Focal Segmental Glomerulosclerosis Drug Product Picture
Figure 2. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Losmapimod Product Picture
Figure 4. SHP-627 Product Picture
Figure 5. Sparsentan Product Picture
Figure 6. TM-5484 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Research Center
Figure 11. Hospital
Figure 12. Others
Figure 13. Focal Segmental Glomerulosclerosis Drug Report Years Considered
Figure 14. Global Focal Segmental Glomerulosclerosis Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Focal Segmental Glomerulosclerosis Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Focal Segmental Glomerulosclerosis Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region in 2019
Figure 19. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region in 2019
Figure 21. Global Focal Segmental Glomerulosclerosis Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Focal Segmental Glomerulosclerosis Drug Revenue in 2019
Figure 23. Focal Segmental Glomerulosclerosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type in 2019
Figure 26. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type in 2019
Figure 28. Global Focal Segmental Glomerulosclerosis Drug Market Share by Price Range (2015-2020)
Figure 29. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application in 2019
Figure 31. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application in 2019
Figure 33. North America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country in 2019
Figure 36. North America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Focal Segmental Glomerulosclerosis Drug Market Share by Type in 2019
Figure 42. North America Focal Segmental Glomerulosclerosis Drug Market Share by Application in 2019
Figure 43. Europe Focal Segmental Glomerulosclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country in 2019
Figure 46. Europe Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country in 2019
Figure 47. Germany Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Focal Segmental Glomerulosclerosis Drug Market Share by Type in 2019
Figure 58. Europe Focal Segmental Glomerulosclerosis Drug Market Share by Application in 2019
Figure 59. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region in 2019
Figure 63. China Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Focal Segmental Glomerulosclerosis Drug Market Share by Type in 2019
Figure 86. Asia Pacific Focal Segmental Glomerulosclerosis Drug Market Share by Application in 2019
Figure 87. Latin America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country in 2019
Figure 90. Latin America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Focal Segmental Glomerulosclerosis Drug Market Share by Type in 2019
Figure 98. Latin America Focal Segmental Glomerulosclerosis Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Share by Application in 2019
Figure 111. North America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Focal Segmental Glomerulosclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
巣状分節性糸球体硬化症（FSGS）治療の世界市場（～2026年） Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney’s filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followe…- 巣状分節性糸球体硬化症（FSGS）の世界市場（～2026年） Focal Segmental Glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults. Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis (FSGS) Market The global Focal Segmental Glomerulosclerosis (FSGS) m…
- フォーカルアドヒージョンキナーゼの世界市場（～2026年） Market Analysis and Insights: Global Focal Adhesion Kinase Market The global Focal Adhesion Kinase market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Focal Adhesion Kinase Scope and Market Size Focal Adhesion Kinase marke…
- 糖尿病性神経障害治療薬の世界市場（～2026年） A drug used to treat mental illness caused by diabetes Market Analysis and Insights: Global Diabetic Neurological Disorder Therapeutic Drug Market The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CA…
- 小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…